Antenatal iron supplementation in sickle cell disease

Area of Science:

• Hematology
• Obstetrics
• Nutritional Science

Background:

• Sickle cell disease (SCD) presents unique challenges during pregnancy.
• Iron status in pregnant women with SCD is not fully understood.
• Routine iron supplementation is common in pregnancy but may not be beneficial for all conditions.

Purpose of the Study:

• To evaluate the efficacy of routine iron supplementation in pregnant women with sickle cell disease (SCD).
• To assess the impact of iron supplementation on maternal iron stores and fetal outcomes.

Main Methods:

• Randomized controlled trial involving 14 pregnant women with SCD (11 SS, 3 SC).
• Participants received either ferrous gluconate or placebo antenatal supplementation.
• Maternal hemoglobin and bone marrow iron content were measured prenatally and 6 weeks postpartum.
• Fetal weights and incidence of pain crises were recorded.

Main Results:

• No participants exhibited iron depletion in bone marrow.
• The iron-supplemented group showed an aggregate gain of 2 grades in iron repletion.
• The placebo group showed an aggregate loss of 4 grades in iron repletion.
• No significant differences were observed in birth weight or pain crisis incidence between groups.

Conclusions:

• Routine iron supplementation is not indicated for pregnant women with SCD.
• Supplementation may lead to excessive iron accumulation in women with adequate or high iron stores.
• Iron supplementation should be based on demonstrated need in this population.